Q-Line Biotech Limited

<table><tr><td>RoCE (%)</td><td>RoCE provides how efficiently our Company generates earnings from the capital employed in the business.</td></tr></table>

## 7. Set forth below are the details of comparison of key performance of indicators with our listed industry peer:

There are no listed companies in India that engage in a business similar to that of our Company. Accordingly, it is not possible to provide a comparison of key performance indicators of industry with our Company.

## 8. Weighted average cost of acquisition

### a) The price per share of our Company based on the primary/ new issue of shares (equity/ convertible securities)

There has been no issuance of Equity Shares other than Equity Shares issued pursuant to a bonus issue on August 28, 2025 and right issue on September 27, 2025 during the 18 months preceding the date of this Draft Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue"):

### b) The price per share of our Company based on the secondary sale/ acquisition of shares (equity shares)

There have been no secondary sale/ acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

### c) Since there are no such transactions to report to under (a) and (b) therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter/ Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of this certificate irrespective of the size of transactions, is as below:

**Primary Transactions:**

(₹ in lakhs)

<table><thead><tr><td>Date of Allotment</td><td>No. of equity shares allotted</td><td>Issue price per equity share (₹)</td><td>Nature of Allotment</td><td>Nature of consideration</td><td>Total Consideration</td></tr></thead><tbody><tr><td>August 28, 2025</td><td>1,41,75,000</td><td>Nil</td><td>Bonus Issue</td><td>Other than Cash</td><td>Nil</td></tr><tr><td>September 27, 2025</td><td>5,24,999</td><td>10/-</td><td>Right Issue</td><td>Cash</td><td>52,49,990</td></tr></tbody></table>

**Secondary Transactions:**

(₹ in lakhs)

<table><thead><tr><td>Date</td><td>Name of Transferor</td><td>Name of Transferee</td><td>No. of Shares</td><td>Price per share</td><td>Adjusted Price per share</td><td>Nature of transaction</td><td>Total Consideration</td></tr></thead><tbody><tr><td>September 25, 2025</td><td>Pushplata Garg</td><td>Saurabh Garg</td><td>54,000</td><td>Nil</td><td>-</td><td>Gift</td><td>Nil</td></tr><tr><td rowspan="4">June 06, 2025</td><td rowspan="2">Amita Garg</td><td>Abhay Agrawal</td><td>75,600</td><td>Nil</td><td>-</td><td>Gift</td><td>Nil</td></tr><tr><td>Amit Agarwal</td><td>3,150</td><td>Nil</td><td>-</td><td>Gift</td><td>Nil</td></tr><tr><td rowspan="2">Saurabh Garg</td><td>Ayush Garg</td><td>3,149</td><td>Nil</td><td>-</td><td>Gift</td><td>Nil</td></tr><tr><td>Shubham Garg</td><td>3,150</td><td>Nil</td><td>-</td><td>Gift</td><td>Nil</td></tr></tbody></table>

**Weighted average cost of acquisition & Issue price:**

<table><thead><tr><td>Types of transactions</td><td>Weighted average cost of acquisition (₹ per Equity Shares)</td><td>Floor price* (i.e. ₹ [•])</td><td>Cap Price* (i.e. ₹ [•])</td></tr></thead><tbody><tr><td>Weighted average cost of acquisition of primary/ new issue as per paragraph 8(a) above.</td><td>NA^</td><td>NA^</td><td>NA^</td></tr><tr><td>Weighted average cost of acquisition for secondary sale/ acquisition as per paragraph 8(b) above.</td><td>NA^^</td><td>NA^^</td><td>NA^^</td></tr></tbody></table>

97